देश: दक्षिण अफ़्रीका
भाषा: अंग्रेज़ी
स्रोत: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
ASPEN LAMOTRIGINE 25 mg TABLETS ASPEN LAMOTRIGINE 50 mg TABLETS ASPEN LAMOTRIGINE 100 mg TABLETS ASPEN LAMOTRIGINE 200 mg TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): ASPEN LAMOTRIGINE 25 mg TABLETS ASPEN LAMOTRIGINE 50 mg TABLETS ASPEN LAMOTRIGINE 100 mg TABLETS ASPEN LAMOTRIGINE 200 mg TABLETS COMPOSITION Each tablet contains: ASPEN LAMOTRIGINE 25 mg TABLETS – Lamotrigine 25 mg ASPEN LAMOTRIGINE 50 mg TABLETS –Lamotrigine 50 mg ASPEN LAMOTRIGINE 100 mg TABLETS –Lamotrigine 100 mg ASPEN LAMOTRIGINE 200 mg TABLETS –Lamotrigine 200 mg PHARMACOLOGICAL CLASSIFICATION A.2.5 Antiepileptics PHARMACOLOGICAL ACTION Lamotrigine blocks voltage-sensitive sodium channels, thereby stabilising neuronal membranes and inhibiting neurotransmitter release, principally that of glutamate, an excitatory amino acid which is thought to play a major role in the generation of epileptic seizures. Pharmacokinetics Lamotrigine is well and completely absorbed from the gut. The absorption is unaffected by food. The time to peak concentration is 1,4 to 4,8 hours. The mean elimination half-life is 25 + 10 hours and the pharmacokinetic profile is linear up to 450 mg, the highest single dose tested. The half-life of lamotrigine is affected by concomitant use of enzyme-inducing drugs such as phenytoin, carbamazepine, phenobarbital or primidone with a mean value of approximately 14 hours. The half-life of lamotrigine increases to approximately 59 hours when co-administered with valproic acid alone (see DOSAGE AND DIRECTIONS FOR USE) Following multiple administration of lamotrigine (150 mg twice daily) there is modest induction of its own metabolism, resulting in a 25% decrease in the elimination half-life at steady state. Lamotrigine is moderately (55%) bound to पूरा दस्तावेज़ पढ़ें